CompletedNot Applicable

The Safety and Efficacy of Fecal Microbiota Transplant (FMT) for Steroid-refractory Graft-versus-host Disease

China46 participantsStarted 2020-04-27

Plain-language summary

This clinical study evaluates the safety and efficacy of fecal microbiota transplantation (FMT) in patients with steroid-refractory graft-versus-host disease (GVHD).

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Able and willing to sign the informed consent form and complete follow-up;
✓. Aged 18-65 years, regardless of gender;
✓. Patients with refractory GVHD.

Exclusion criteria

✕. life-threatening or associated with severe non-GvHD complications;
✕. Persistent malignant conditions;
✕. Patients who have undergone second or multiple hematopoietic stem cell transplants;
✕. History of severe allergic reactions;
✕. Any condition that the investigator considers unsuitable for inclusion (such as any history, treatment history, or abnormal test data that may confound the study results, interfere with full participation in the study, or harm the patient's interests);

What they're measuring

Overall Response Rate (ORR)

Timeframe: 12 weeks

Trial details

NCT IDNCT06938165

SponsorNanfang Hospital, Southern Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-30

View on ClinicalTrials.gov More GVHD trials